ZNTL - Zentalis: A Buy As Small Molecule Trials Continue To Advance

2023-08-24 09:42:43 ET

Summary

• Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies.
• The company's financials show a solid cash position and efficient allocation of resources.
• Zentalis has a diverse pipeline of oncological therapies in various stages of clinical trials, targeting different types of cancer.

Zentalis Pharmaceuticals ( ZNTL ) is a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small-molecule therapeutics that target various cancer indications. The company is working to harness advanced technologies and a robust pipeline that aims to transform the treatment landscape for patients suffering from various oncological diseases.

The dedication to creating targeted therapies positions Zentalis in the competitive biopharmaceutical arena, reflecting a balance of innovation and practical application. This overview offers a look into why the company remains a solid investment from a growth perspective.

Financials

Zentalis' second quarter 2023 financial results reflect a company in active pursuit of its oncological research and development mission, coupled with a strategic and careful allocation of resources.

The company's cash and marketable securities position, standing at $553.0 million as of June 30, 2023, offers a solid financial foundation. The management's projection that these funds will be sufficient to cover operating expenses and capital expenditure requirements into 2026 reveals a healthy cash runway and signals confidence in the firm's fiscal management.

R&D expenses form a core part of Zentalis' financials, reaching $42.7 million in the quarter ended June 30, 2023, slightly less than the previous year's same period. The decrease of $1.1 million, mainly from collaboration costs, clinical trials, and R&D supplies, illustrates targeted spending and a focus on efficiency. Simultaneously, the increase in Zentera Therapeutics cost sharing and consulting expenses shows ongoing investments in key areas.

General and administrative expenses, reduced to $15.7 million during this quarter from $19.6 million in the same quarter last year, demonstrate Zentalis' commitment to optimizing non-core expenses. The $3.9 million decrease, primarily due to non-cash, stock-based compensation and other personnel expenses, illustrates judicious management.

Zentera-related expenses are noteworthy, with the company incurring a one-time expense of $45.6 million due to regaining worldwide development and commercialization rights for ZN-c5 in certain Asian countries, including China. This strategic move may provide Zentalis with greater control over critical parts of its product pipeline, despite the immediate financial impact.

Taking into consideration the burn rate, the company expects the existing cash to sustain operations into 2026 - this suggests that they anticipate lower ongoing expenses or additional income streams to support their projections.

Pipeline

Zentalis Pharmaceuticals' product pipeline for 2023 has a suite of oncological therapies, all in various phases of clinical trials, targeting crucial areas of cancer treatment.

Azenosertib, acts as a WEE1 inhibitor and offers a novel approach to combating cancer by blocking the DNA damage response pathway. The focus on solid tumors such as ovarian cancer and breast cancer emphasizes its potential applicability to various cancer types. Positive Phase 1 trial safety and effectiveness data, coupled with promising Phase 1b results at the 2023 American Society of Clinical Oncology ((ASCO)) Annual Meeting, validate the company's dedication to this innovative treatment approach.

ZN-c5 is another significant product candidate, an oral selective estrogen receptor degrader (SERD) designed to address hormone receptor-positive breast cancer. Zentalis is attempting to overcome the existing limitations of SERDs with ZN-c5, which reflects a deep understanding of both the medical need and the scientific challenges at hand. The company's success in completing enrollment in its Phase 1 trial indicates steady progress.

ZN-d5, the company's BCL-2 inhibitor, targets a different angle by inducing programmed cell death in cancer cells. This approach could potentially revolutionize treatment for hematological malignancies and solid tumors, particularly for those resistant to chemotherapy. The initiation of dosing in its Phase 1 trial exhibits the company's ongoing commitment to innovative therapy.

ZN-e4 , an epidermal growth factor receptor inhibitor, targets a wide range of solid tumors by blocking the activity of EGFR, a prominent player in cell growth and survival in cancer. The completion of enrollment in its Phase 1 trial underscores the potential of this approach, with eagerly anticipated data to be reported later in 2023.

Zentalis' collaborations with industry giants like Pfizer ( PFE ), Roche Diagnostics , Foundation Medicine , and Tempus further support its development efforts. Such collaborations often enable shared expertise and resources, fostering the potential success of the pipeline. The strong cash position underlines the company's financial capability to support these vital research and development initiatives.

Azenosertib's Promising Dosing Advancements in Oncology

Zentalis Pharmaceuticals' announcement regarding the recommended Phase 2 dose (RP2D) for azenosertib marks an essential milestone in the company's oncological pursuits. The RP2D for azenosertib as a monotherapy, settled at 400 mg daily on a 5-day on, 2-days off weekly administration schedule, has more than doubled the steady-state drug exposure compared to continuous dosing. This enhanced exposure not only achieved promising efficacy signals but also maintained safety and improved tolerability.

The announcement reveals a new optimized monotherapy dosing schedule that Zentalis believes has unlocked the therapeutic potential of WEE1 inhibition. With promising results demonstrated in both monotherapy and combination with chemotherapy, the confidence in azenosertib's potential to aid patients with difficult-to-treat cancers is significantly heightened. The focus on platinum-resistant and platinum-sensitive ovarian cancer emphasizes the company's intent to address a majority of ovarian cancer patients, an area where unmet medical needs persist.

The summary of Phase 1 Monotherapy Dose Optimization Data showcases some intriguing results. The total of 127 heavily pretreated patients who were treated with azenosertib shows the substance's substantial applicability. The comparison between intermittent and continuous dosing schedules reveals a preference for the former, with higher confirmed objective response rates (ORR) in certain cancer subgroups, a result that can be crucial for patient outcomes.

The intermittent dosing also presented improvements in safety and tolerability compared to continuous dosing, with no discontinuations due to treatment-related adverse events (TRAEs) observed in the intermittent cohorts. This data supports the idea that the new RP2D is both effective and well-tolerated by patients, a critical aspect in cancer treatment.

The company's current enrollment at the new RP2D in three ongoing Phase 2 trials also reflects a continued commitment to understanding the potential of azenosertib in specific patient populations. With indications targeting various forms of resistant ovarian cancer and uterine serous carcinoma (USC), Zentalis is expanding its potential impact.

Mechanistic Risks

For Zentalis's product candidates, there are several technical risks associated with each that must be discussed. Azenosertib, brings about the challenge of precisely blocking the DNA damage response pathway without affecting other vital cellular functions. While the function of WEE1 is to regulate the cell cycle, any off-target effects could lead to uncontrolled cell growth or other disruptions in the cell cycle. Moreover, resistance mechanisms might develop over time in response to WEE1 inhibition, rendering the treatment less effective.

ZN-c5 targets a highly complex hormone pathway. Its development poses risks related to the accurate binding and degradation of the estrogen receptor without impacting other hormone receptors. Unintended interference with hormonal balance could lead to a range of systemic side effects. Additionally, the complexity of overcoming the limitations of existing SERDs, such as poor oral bioavailability and low potency, remains a significant challenge.

ZN-d5 must navigate the complexity of selectively inducing apoptosis in cancer cells without affecting healthy cells. BCL-2's role in preventing cell death is critical in normal cellular function, and any non-selective action might lead to unintended cell death in non-cancerous tissues. Combining ZN-d5 with another BCL-2 inhibitor like venetoclax may also lead to unforeseen synergistic effects that could amplify toxicity.

ZN-e4's inhibition of EGFR presents risks associated with specificity and resistance. EGFR plays an essential role in stimulating cell growth and survival, and its inhibition must be highly targeted to prevent unwanted effects on non-cancerous cells. The potential for resistance to EGFR inhibition and the risk of toxicities from combining with other EGFR inhibitors like osimertinib must be carefully observed.

Across the entire portfolio, common risks include the potential for unforeseen toxicities, especially as the products move into later-stage trials with more extensive patient populations. The complexity of the targeted pathways, each with its nuances and potential for off-target effects, underscores the need for careful and ongoing monitoring. Additionally, the strategic collaborations with other companies must be managed adeptly to ensure that they contribute positively to the development process without introducing new complications.

Competitors

With regards to azenosertib, competitors such as AstraZeneca ( AZN ) have been working on their WEE1 inhibitor, adavosertib . While adavosertib has shown promise in early-phase trials, it might lack the optimized dosing schedule that azenosertib offers, which more than doubled steady-state drug exposure and maintained safety and tolerability. The unique dosing schedule and promising efficacy of azenosertib could set it apart from its competitors in this space.

In the SERD domain, companies like Genentech are advancing products such as giredestrant . However, Zentalis's ZN-c5 may offer advantages in overcoming limitations like poor oral bioavailability and low potency that have plagued existing SERDs. By addressing these specific challenges, ZN-c5 might be better positioned to succeed in the estrogen receptor-positive breast cancer market.

When assessing BCL-2 inhibitors like ZN-d5, it's important to consider competitors like AbbVie's venetoclax ( ABBV ). Although venetoclax has demonstrated effectiveness as a BCL-2 inhibitor, Zentalis's approach of combining ZN-d5 with venetoclax itself in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) might result in synergistic effects that could lead to improved therapeutic outcomes. This unique combination approach might differentiate ZN-d5 from other BCL-2 inhibitors on the market.

In the realm of EGFR inhibitors, Zentalis faces competition from drugs such as erlotinib (tarceva) by Roche. However, ZN-e4's development as a monotherapy and in combination with other EGFR inhibitors like osimertinib may provide an edge in treating EGFR-mutant non-small cell lung cancer ((NSCLC)). The strategic combination therapy might lead to enhanced efficacy and more personalized treatment plans.

Verdict at Current Value

Zentalis Pharmaceuticals has strategically positioned itself as a significant player in the burgeoning field of oncological research. The diversified pipeline, rich in clinically differentiated small molecule therapies like WEE1 and EGFR inhibitors, suggests multiple avenues for growth and risk mitigation. Collaborations with industry giants further endorse the company's potential, signaling an underappreciated intrinsic value not fully reflected in conventional metrics.

As for valuation, the company's market cap of $1.8 billion and a higher-than-sector-average P/B ratio of 3.42 may appear ambitious. However, Zentalis' robust cash position, projected to sustain operations into 2026, and the strategic regaining of development rights in key Asian markets make a compelling case for this elevated valuation. While these numbers indicate market expectations of high growth, the company’s proven fiscal responsibility and multifaceted approach to oncological treatment underpin these expectations.

The ostensibly high valuation can still be seen as an attractive entry point for investors with an eye on long-term growth dynamics rather than a pure value approach, especially given Zentalis' differentiated strategies and financial preparedness. Despite existing competition, Zentalis is carving a unique path in the rapidly evolving oncology landscape, enhancing confidence in its potential for commercial success.

For further details see: